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To elucidate the role of ameba-associated microorgan-
isms (AAMs) as etiologic agents of pneumonia, we
screened for Legionella spp., Parachlamydia acanthamoe-
ba,  Afipia sp., Bosea  spp.,  Bradyrhizobium  spp.,
Mesorhizobium amorphae,  Rasbo bacterium, Azorhi-
zobium caulinodans, Acanthamoeba polyphaga mimivirus,
and conventional microorganisms in 210 pneumonia
patients in intensive-care units by using culture, poly-
merase chain reaction, and serologic testing. These result-
ed in 59 diagnoses in 40 patients. AAMs and non-AAMs
were implicated in 10.5% of the patients. The infectious
agents were identified in 15 patients: Acanthamoeba
polyphaga mimivirus, 8; Legionella pneumophila, 3;
L. anisa, 1; Parachlamydia  sp., 1; Bosea massiliensis,
L. worsleiensis, L. quinlivanii, and L. rubrilucens, 1; and
M. amorphae and R. bacterium, 1. A. polyphaga mimivirus
was the fourth most common etiologic agent, with a higher
seroprevalence than noted in healthy controls. This finding
suggested its clinical relevance. Therefore, AAM might
cause nosocomial pneumonia and should be suspected
when conventional microbiologic results are negative.
P
neumonia is a major cause of illness and death
throughout the world (1). Approximately 600,000 per-
sons with pneumonia are hospitalized each year, and 64
million days of restricted activity occur because of this dis-
ease (2). Pneumonia is associated with high death rates, in
particular, 30% for community-acquired pneumonia (3).
Hospital-acquired pneumonia occurs in 0.5% to 1% of
hospitalized patients, which represents 10%–15% of all
nosocomial infections; pneumonia is the most common
cause of nosocomial infection in intensive-care units
(ICUs) (4). The etiologic agent of community-acquired
pneumonia remains unknown in 20% to 50% of cases (5),
and several pathogens that may cause pneumonia seem to
be underestimated (6–8). 
Microbiologically contaminated water distribution sys-
tems have been linked to outbreaks of hospital- and com-
munity-acquired pneumonia (9,10). Water-associated
microorganisms, such as Legionella  spp.,  Pseudomonas
spp., Stenotrophomonas spp., Burkholderia  spp., and
Acinetobacter spp., colonize hospital water supplies and
have been causally associated with cases of hospital-
acquired pneumonia (10). There is also a growing concern
that water–associated microorganisms, for example,
Legionella spp., Afipia spp., Bosea spp., Bradyrhizobium
spp.,  Mesorhizobium  spp.,  Rasbo bacterium, Parachla-
mydia spp., and Acanthamoeba polyphaga mimivirus, may
be associated with amebas (11–13). We previously demon-
strated that patients with nosocomial pneumonia who
received care in a hospital near a contaminated water dis-
tribution system showed strong serologic evidence of
exposure to these microorganisms (14). Specimens from
12 (40%) of 30 patients in an ICU seroconverted to
microorganisms known to survive in an aquatic environ-
ment in the intracellular niche provided by free-living
Acanthamoebae (15). These seroconversions were associ-
ated with ventilator-associated pneumonia, especially in
patients for whom no etiologic agent was found by usual
microbiologic investigations. We have also reported sero-
logic evidence of exposure to an emerging giant virus that
is resistant to phagocytic destruction by ameba, which we
named A. polyphaga mimivirus (www-micro.msb.le.ac.uk/
3035/VirusGroups.html), in 26 patients with ventilator-
associated pneumonia at another ICU (12,13,16). Using
this rationale, we evaluated infections with ameba-associ-
ated microorganisms (AAM) in a larger series of patients
with pneumonia hospitalized in Marseille, France. Our
goal was to identify typical pathogens as well as emerging
AAMs (12–15,17–20). 
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Study Population
All patients admitted to the ICU of Sainte-Marguerite
Hospital in Marseille, France, with clinically suspected
pneumonia over an 18-month period ending in June 2003
were enrolled in a prospective study. For all patients, the
clinical suspicion of pneumonia was based on the presence
of new or progressive pulmonary infiltrates on chest radi-
ograph along with 2 of the following features: pyrexia with
a temperature >38.5°C, purulent tracheobronchial secre-
tions, and leukocytosis with a total peripheral leukocyte
count >12, 000/mm3. All episodes of suspected ventilator-
associated pneumonia with fever and pulmonary density
were retrospectively reevaluated and all differential diag-
noses were excluded (21). Since patients might have been
treated for pneumonia more than once during the 18-month
study period, episodes rather than individual patients were
the unit of analysis. Beginning from the time of admission,
all occasions on which pneumonia had been diagnosed in
individual patients were considered a single episode of
pneumonia unless the interval between 2 such occasions
exceeded 30 days. Excluded from the final analyses were
patients who did not recover between 2 episodes of pneu-
monia.
Data Collection
Samples used for this study resulted from the current
residual sampling strategy of the ICU; no supplement sam-
pling was performed for the study. The identity of patients
who provided samples and questionnaire information
before the study remained confidential according to
French law. We collected clinical data by using a standard-
ized questionnaire that included sociodemographic data
(age, sex), medical history (chronic obstructive bronchop-
neumonia, asthma, cystic fibrosis, smoking and alcohol
habits, immunosuppression, cancer, HIV infection, malnu-
trition, tuberculosis), hospitalization data (surgery, inhala-
tion therapy, duration of ventilation, and antimicrobial
drug use), and type of pneumonia (nosocomial or commu-
nity acquired). Acute respiratory distress syndrome
(ARDS) was defined according to the American-European
consensus (22). Information on immunosuppression was
obtained for patients with a history of cancer, organ trans-
plants, splenectomy, HIV infection (when the CD4+ T-cell
count was <200 cells/µL), and immunosuppressor or
steroid treatment (>0.5 mg/kg prednisone for >30 days or
>5 mg/kg prednisone for >5 days).
Study Design
The diagnostic strategy included bronchoalveolar
lavage (BAL) fluid, blood cultures, and serologic and urine
samples. BAL was performed by wedging the broncho-
scope into a subsegment of the area of the lung when great-
est abnormality was seen on a radiograph, or when the dis-
ease was diffuse, into the lingual or right middle lobe.
Normal saline was sequentially instilled in 20-mL aliquots
and sectioned into sterile traps for microbiologic testing
for AAMs. This testing included culturing onto an agar
base containing buffered charcoal yeast extract and
enriched with α-ketoglutarate and L-cysteine (23) (Oxoid,
Dardilly, France) with cefamandole, polymyxin B, and
anisomycin for Legionella spp. cultivation; coculture with
amebas as previously reported (24,25) for AAM; and
TaqMan real-time polymerase chain reaction assay for
enhanced detection of AAMs (Legionella pneumophila, L.
anisa, Parachlamydia spp., Bosea spp., and A. polyphaga
mimivirus). DNA was extracted from BAL samples by
using the QIAMP tissue kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. Acute- and
convalescent-phase serum samples were drawn into vacu-
tainer tubes (Becton Dickinson, Rutherford, NJ, USA) and
tested by immunofluorescence assay for antibodies to L.
pneumophila, L. anisa, L. bozemanii, L. longbeachae, L.
micdadei, and other AAMs (15,18), including
Parachlamydia acanthamoeba (strain BN 9 and “Hall’s
coccus”), Afipia birgiae, A. broomeae, A. clevelandensis,
A. felis, A. felis genospecies A, Afipia genospecies 1–3, A.
massilliae,  Azorhizobium caulinodans,  Bosea eneae,  B.
massiliensis, B. thiooxydans, B. vestrisii, Bradyrhizobium
japonicum, B. liaoningense, L. quinlivanii, L. rubrilucens,
L. worsleiensis, Mesorhizobium amorphae, Rasbo bacteri-
um, and Acanthamoeba polyphaga mimivirus (13,15). A
urine sample was tested for L. pneumophila serogroup 1
antigen by enzyme-linked immunosorbent assay (26)
(Binax, Inc., Portland, ME, USA). Data on non-AAMs iso-
lated from BAL or blood cultures were obtained by con-
ventional or specific procedures (culture performed on
Löwenstein-Jensen medium, shell-vial culture for
cytomegalovirus, and inoculation onto continuous cell
lines for indirect immunofluorescence assay for herpes
simplex virus). Mycoplasma pneumonia, Chlamydia pneu-
moniae, C. psittacci, Coxiella burnetii, influenza viruses A
and B, and adenovirus were also identified.
Main Outcome Measures
Two groups of microorganisms were defined. The first
was AAM (Legionella  spp.,  Afipia spp.,  Bosea spp.,
Bradyrhizobium spp., Mesorhizobium spp., Rasbo bacteri-
um,  Parachlamydia  spp., and A. polyphaga mimivirus).
The second group was other water-associated microorgan-
isms (Pseudomonas aeruginosa and AAM). Diagnosis of
AAM infection was classified as having a strong or low
level of evidence. The role of an infectious agent in the
diagnosis reflected several factors, which included the
relationship of the anatomic site of detection to the lung,
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was a known cause of pneumonia. 
Strong evidence for AAM included 1) positive BAL
culture, 2) 4-fold increase in antibody titer between acute-
and convalescent-phase serum samples or seroconversion
from 0 to 1:128 for L. pneumophila, L. anisa, L. boze-
manii, L. micdadei, and L. longbeachae; and from 0 to 1:
100 for L.  quinlivanii,  L.  rubrilucens,  L. worsleiensis,
Afipia  spp.,  Bosea spp.,  Bradyrhizobium spp.,
Mesorhizobium spp., Parachlamydia spp., R. bacterium,
and A. polyphaga mimivirus; and 3) positive results for L.
pneumophila antigen. 
Alow level of evidence for AAM included a stable anti-
body titer of >1:256 for L. pneumophila, L. anisa, L. boze-
manii,  L.  micdadei, and L.  longbeachae; >1:400 for L.
quinlivanii,  L. rubrilucens,  L. worsleiensis,  Afipia  spp.,
Bosea spp., Bradyrhizobium spp., Mesorhizobium spp., R.
bacterium, and A. polyphaga mimivirus; and >1:200 for P.
acanthamoeba.
Statistical Analysis
Results are expressed as mean ± standard deviation
(SD). Continuous variables were compared by using the
Student t-test or the nonparametric Mann Whitney U test
when they could not be judged normal. Categoric variables
were compared by using the χ2 test or Fisher exact test
when appropriate. Statistical significance was established
at p<0.05. All analyses were performed with SPSS version
10 software (SPSS Inc., Chicago, IL, USA).
Results
Atotal of 157 patients with 210 episodes of pneumonia
were included in the study. The frequency of pneumonia
episodes per patient was 1 in 123 patients, 2 in 22 patients,
3 in 7 patients, 4 in 3 patients, and 5 in 2 patients. The
mean ± SD age was 61.6 ± 16.1 years (range 19–99) and
73.8% of the patients were male. Samples were collected
in 62 episodes of community-acquired pneumonia, 120
episodes of nosocomial pneumonia, and 28 episodes of
mixed pneumonia (community-acquired, complicated with
a nosocomial infection). Data collected for 201 episodes of
pneumonia indicated a prevalence of 18.4% with chronic
obstructive bronchopneumonia, 6.5% with asthma, 0.5%
with cystic fibrosis, 41.8% with smoking habits (19% in
males vs. 26% in females; p = 0.004), 17.4% with alcohol
consumption, 37.3% with immunosuppression (3 cases of
prolonged steroid treatment for inflammatory disease
[1.5%], 3 HIV infections [1.5%], 2 splenectomies [1.0%],
3 lung transplants [1.5%], 8 kidney transplants [4.0%] and
57 cancers [28.4%]), 6.0% with malnutrition, 5.5% with a
history of tuberculosis, 29.8% with previous surgery
(62/208), 38.4% with probable or certain inhalation thera-
py (78/203), and 38.9% with antimicrobial drug therapy
for >1 week (70/180). The mean ± SD duration of hospi-
talization and ventilation was 22.9 ± 32.6 days (range
0–371) and 16.3 ± 19.9 days (range 0–101 days), respec-
tively. Data on antimicrobial treatment before BAL was
available for 208 patients. Of these, 116 (55.8%) received
an antimicrobial drug, 16 (7.7%) an antiviral drug, and 18
(8.7%) an antimycotic drug. 
Some patients had several definite or possible
pathogens. Atotal of 230 documentations corresponding to
40 etiologic agents were identified in 152 (72.4%) of 210
episodes of pneumonia. Eighty-six (41.0%) BAL speci-
mens were contaminated with fungi. Table 1 summarizes
the non-AAMs identified as definite (28 in 27 [12.9%] of
210 episodes) or possible (143 in 115 [54.8%] of 210
episodes). 
Laboratory investigations for AAMs detected 59 diag-
noses in 40 (19.0%) patients. More than 1 AAM was
observed in 56 episodes of pneumonia (26.7%); 39
(18.6%) had 2 AAMs, 11 (5.2%) had 3 AAMs, 3 (1.4%)
had 4 AAMs, 2 (1.0%) had 5 AAMs, and 1 (0.5%) had 6
AAMs. Ten patients had serologic evidence of mixed
infections with AAMs. Of the 40 patients with document-
ed AAM infections, 18 (8.6% of our series) had evidence
of AAMs (Table 2); 9 of these patients showed a high level
of evidence. Evidence of pneumonia caused by unique
AAMs was obtained in 13 patients. Of these, 5 had pneu-
monia caused by A. polyphaga mimivirus, 5 caused by L.
pneumophila, 2 caused by L. bozemanii, and 1 caused by
Parachlamydia sp. Mixed infections in these patients with
2, 3, and 5 AAMs were observed in 1, 2, and 2 patients,
respectively. A unique AAM was observed in 13 patients
(5 with A. polyphaga mimivirus, 5 with L. pneumophila, 2
with L. bozemanii, and 1 with Parachlamydia sp.).
A total of 22 (10.5%) of 210 episodes of pneumonia
were observed in which both AAMs and conventional
microorganisms were detected (Table 3). Six patients had
diagnoses of AAM infection with a high level of evidence.
Three of these 6 patients also had definite diagnoses of
pneumonia caused by AAMs, and 3 others had a possible
diagnosis of pneumonia caused by non-AAMs. Sixteen
patients had diagnoses of pneumonia caused by AAMs
with a low level of evidence. Three of these patients also
had definite diagnoses of pneumonia caused by non-
AAMs, and 13 had possible diagnoses of pneumonia
caused by non-AAMs.
Fifteen patients were identified as having definite cases
of pneumonia caused by AAMs. This subgroup (of whom 1
had a definite diagnosis of S. aureus infection and 1 of C.
pneumoniae infection), included 8 patients with pneumonia
caused by A. polyphaga mimivirus, 3 with pneumonia
caused by L. pneumophila, and 5 who seroconverted. Those
who seroconverted included any patient with seroconver-
sion for L.  anisa,  Parachlamydia  sp.,  B.  massiliensis,
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phae, and R. bacterium. In addition, 1 who seroconverted
also had a diagnosis of infection with P. aeruginosa and B.
alpica. Eleven patients had possible infections with
Legionella sp. (L.  pneumophila in 7, L. bozemanii in 3,
and L. anisa in 1), and 19 patients had possible infections
with atypical organisms (A. polyphaga mimivirus in 7, B.
japonicum in 6, B. massiliensis in 4, B. liaoningense in 3.
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in 2, and L. rubrilucens in 1). 
The frequency of infections with AAMs is summarized
in Table 4. A. polyphaga mimivirus, which was identified
in 15 (7.1%) of 210 episodes of pneumonia, was the most
common AAM. Legionella sp. were identified in 14
episodes. Three of these patients had mixed infections (L.
pneumophila and L. anisa in 1, L. pneumophila and L.
rubrilucens in 1, and L. quilivanii, L. rubrilucens, and L.
worsleiensis in 1). L. pneumophila, which was identified in
10 (4.8%) of 210 episodes, was the second most frequent-
ly documented AAM. Bradyrhizobium sp. was identified
in 9 patients; 6 of them were also infected with B. japon-
icum. Five of 8 patients infected with Bosea sp. were also
infected with B. massiliensis. Four patients had serologic
evidence of mixed infection with B.  japonicum and  B.
massiliensis. The 7 most common etiologic agents were P.
aeruginosa (20.5%),  S.  aureus (13.8%), herpes simplex
virus (8.1%), A. polyphaga mimivirus (7.1%),
cytomegalovirus (6.2%), Escherichia coli (5.7%), and L.
pneumophila (4.8%). If one considers only diagnoses with
a high level of evidence, the 4 most common etiologic
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(3.8%), E. coli (1.9%), and L. pneumophila (1.4%). 
Adiagnosis was more frequent in a nosocomial context
than outside a hospital (79.1% vs. 54.8%, p<10–3), espe-
cially for P.  aeruginosa  (p<10–6). Water-associated
microorganisms were less likely to be identified in a com-
munity-acquired context than in a nosocomial context
(30% vs. 50%, p = 0.005). Duration of hospitalization and
ventilation were longer for patients infected with the
water-associated microorganisms than for patients not
infected (29 days vs. 19 days p = 0.015 and 21 days vs. 13
days, p = 0.008, respectively). Therapy with antimicrobial
agents and a history of cancer were also more frequent in
patients infected with water-associated microorganisms
(54% vs. 30%, p = 0.001 and 39% vs. 22%, p = 0.014,
respectively). Patients who seroconverted for A. polypha-
ga mimivirus used alcohol more frequently than others in
the study (44% vs. 18%, p = 0.05).
Discussion
We conducted this study to determine the role of AAMs
as causative agents of pneumonia in patients in an ICU.
Concerns have been reported about the role of inline med-
ication nebulizers contaminated with water-associated
microorganisms, AAMs, or both (11,14,15). Other
microorganisms, including Legionella-like amebal
pathogens,  P.  acanthamoeba,  Afipia sp.,  Bosea sp.,
Bradyrhizobium sp., Mesorhizobium sp., and A. polyphaga
mimivirus, have also been reported (14,19,20,27). Our
results indicate that AAMs represented 25.3% (59/233) of
all documented causes of pneumonia and that 19.0%
(40/210) of all episodes of pneumonia were associated
with AAMs. 
Marrie et al. reported that Legionella-like amebal
pathogens might play a role in pneumonia, usually as co-
infecting organisms (18). In 18 patients (8.6%), the role of
AAMs were well documented. Nine of these patients had a
high level of evidence for AAMs. Both conventional
microorganisms and AAMs were implicated in 22 (10.5%)
cases. However, 6 of them had high levels of evidence for
AAM infections. Three of these 6 patients had documented
infections with L.  pneumophila, L. anisa, and A. polypha-
ga mimivirus and low levels of infection with herpes sim-
plex virus, S. marcescens, and P. aeruginosa. The serologic
evidence obtained from these patients demonstrates only
that they were infected by these bacteria or a cross-reactive
microorganism, not that these bacteria caused their pneu-
monia. However, the fact that only 8.6% had only indirect
evidence of AAM infection raises questions about the
potential pathogenic role of AAMs in pneumonia. 
A. polyphaga mimivirus was the fourth most common
cause of pneumonia in our study. This finding suggests that
this organism may be clinically relevant. However, sever-
al lines of evidence now indicate that ameba-resisting
microorganisms other than Legionella sp. are associated
with both community- and hospital-acquired pneumonia
(19,28). La Scola et al. (13) and Marrie et al. (18) have
reported that the seroprevalence of Legionella was higher
than that of other AAMs. Except for L. pneumophila find-
ings, our results agree. The seroprevalence of Legionella
(7.1%) in our series was lower than that reported by others
in community-acquired (9.7%) and hospital-acquired
(19.2%) pneumonia (13). However, this prevalence was
significantly higher (p<0.002) than that observed (2.3%) in
a healthy control population (13). These data also suggest
that some patients with ventilator-associated pneumonia
might have been in contact with A. polyphaga mimivirus or
other cross-reactive antigens. These results raise questions
about the pathogenic potential of the largest virus known
or cross-reactive antibodies to an unknown organism (13). 
We observed a significantly lower prevalence of sero-
conversion (p<10-2) for other AAMs than was found in a
previous series: 32 (15.2%) of 210 serologically diagnosed
cases of AAM pneumonia compared with 12 (40.0%)
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evidence (e.g., seroconversion) obtained in this study
strongly suggests that this patient population may have
been exposed to the most common water ameba-associat-
ed bacteria in their environment (15). No environmental
investigations were performed in our epidemiologic sur-
vey. The lower seroprevalence of AAMs in our patients
suggest that they may have had less exposure in our hospi-
tal ICU compared with that observed in previous studies. 
Interest in free-living amebas has grown over the last
decade with reports of their pathogenic potential (11,29)
and the role of amebas as reservoirs for L. pneumophila
and other AAMs (12–15,17,27,30,31). Since respiratory
care protocols use only sterile water, 2 possible routes of
infection with AAMs include a breach in protocol enforce-
ment and handborne AAMs. Adherence to these protocols
and use of water filters ensures better protection of water
supplies, as is the case in our ICU. 
An interesting finding was that ≈44.8% of the patients
with severe pneumonia had mixed causes. AAM was
implicated in 12.9% of these patients. Fagon et al. report-
ed that only one third of the therapeutic regimens proposed
for pneumonia patients needing ventilators were effective
(32). Because the recommended empiric approaches in
guidelines are based on microbial patterns derived from
several epidemiologic surveys (33), clinicians need to
know the local, regional, and global patterns of microbial
populations and the possibility of emerging pathogens
such as AAMs. If these microorganisms are human
pathogens, they will influence the choice of antimicrobial
drugs for empiric treatment because most are resistant to
carboxypenicillins, ureidopenicillins, third-generation
cephalosporins, and fluoroquinolones, which are common-
ly used in the ICU.
AAMs may cause ventilator-associated pneumonia and
should be suspected when results of conventional microbi-
ologic investigations are negative (11,15,19,28). Adiagno-
sis is rarely available at the time treatment with
antimicrobial agents is begun. Thus, the prevailing situa-
tion warrants better diagnosis of pneumonia and identifica-
tion of new lung pathogens such as AAMs. Recognizing
the emerging pathogens responsible for pneumonia should
be a major public health concern because the knowledge of
predominant microbial patterns will help provide the basis
for rational empiric antimicrobial treatment.
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